Engineering time-controlled immunotherapy

Science. 2022 Dec 16;378(6625):1175-1176. doi: 10.1126/science.adf5318. Epub 2022 Dec 15.

Authors

Emanuel Salazar-Cavazos¹, Grégoire Altan-Bonnet¹

Affiliation

¹ Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

PMID: 36520890
DOI: 10.1126/science.adf5318

Abstract

Designer lymphocytes expand the dynamic range of possibilities for treating disease.

MeSH terms

Cell Engineering
Humans
Immunotherapy, Adoptive*
Neoplasms* / therapy
Receptors, Chimeric Antigen* / genetics
Receptors, Chimeric Antigen* / immunology
T-Lymphocytes* / immunology
T-Lymphocytes* / transplantation

Substances

Receptors, Chimeric Antigen